Clinically Relevant Study End Points in Rectal Cancer

  • Carlos Fernandez-Martos
  • Angel Guerrero
  • Bruce Minsky
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 196)

Abstract

In rectal cancer currently there are no clearly validated early end points which can serve as surrogates for long-term clinical outcome such as local control and survival. However, the use of a variety of response rates (i.e. pathological complete response, downsizing the primary tumor, tumor regression grade (TRG), radiological response) as endpoints in early (phase II) clinical trials is common since objective response to therapy is an early indication of activity. Disease-free survival (DFS) has been proposed as the most appropriate end point in adjuvant trials and is one of the most frequently used in newer rectal cancer trials. Due to the devastating nature of local recurrence in locally advanced rectal cancer, local control (which is itself a subset of the overall DFS endpoint) is still considered an important endpoint. Recently, circumferential resection margin (CRM) has been proposed as novel early end point because the CRM status can account for effects on DFS and overall survival after chemoradiation, radiation (RT), or surgery alone. Consensus is needed to define the most appropriate end points in both early and phase III trials in locally advanced cancer.

Keywords

Local Recurrence Rectal Cancer Maximally Tolerate Dose Total Mesorectal Excision Circumferential Resection Margin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aschele C, Cionini L, Lonardi S et al. (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780Google Scholar
  2. Barbaro B, Fiorucci C, Tebala C et al (2009) Locally advanced rectal cancer: mr imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 250:730–739PubMedCrossRefGoogle Scholar
  3. Bernardo HL et al. (2007) Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 13(22):6719 Nov 15Google Scholar
  4. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRefGoogle Scholar
  5. Bonnetain F, Bosset J, Gerard J et al. (2011) An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? J Clin Oncol 29(suppl; abstr 3506)Google Scholar
  6. Bosset JF, Calais J, Mineur L et al (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 23:5620–5627PubMedCrossRefGoogle Scholar
  7. Bouzourene H, Bosman FT, Seelentag W (2002) Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94:1121–1130PubMedCrossRefGoogle Scholar
  8. Bujko K, Nowacki MP, Kepka L et al. (2005) Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial. Comparing short-term radiotherapy vs chemoradiation. Colorectal Dis 7:410–416Google Scholar
  9. Bujko K, Nowacki M, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223PubMedCrossRefGoogle Scholar
  10. Bujko K, Glynne-Jones R, Bujko M (2010) Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 21(9):1743–1750PubMedCrossRefGoogle Scholar
  11. Burzykowski T, Buyse M, Yothers G (2008) Exploring and validating surrogate endpoints in colorectal cáncer. Lifetime Data Anal 14:54–64PubMedCrossRefGoogle Scholar
  12. Capirci C, Valentini V, Cionini L et al (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72:99–107PubMedCrossRefGoogle Scholar
  13. Chari RS, Tyler DS, Anscher MS et al (1995) Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 221:778–786PubMedCrossRefGoogle Scholar
  14. Chetty R, Gill P, Govender D et al. (2012) A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation. Virchows Arch Jan 13. [Epub ahead of print]Google Scholar
  15. Dancey JE et al (2010) Biomarker studies in early clinical trials of novel agents guidelines for the development and incorporation of novel agents. Clin Cancer Res 16:1745–1755PubMedCrossRefGoogle Scholar
  16. Dworak O, Kelholz L, Hoffman A (1997) Pathological feature of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRefGoogle Scholar
  17. Eisenhauer EA (1998) Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel clavel lecture, held at the 10th NCI-EORTC conference on new drugs in cancer therapy. Ann Oncol 9:1047–1052. Amsterdam, 16–19 Jun 1998Google Scholar
  18. Fernandez-Martos C, Aparicio J, Bosch C Et al. (2004) Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II study with 3 years follow-up. J Clin OncolGoogle Scholar
  19. Fernandez-Martos C, Safont M, Feliu J et al. (2010) Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): a GEMCAD study. Proc Am Soc Clin Oncol 28:Abstr TPS 196Google Scholar
  20. Fernandez-Martos C, Estevan R, Salud A et al. (2012) Neoadjuvant capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. J Clin Oncol 30, 2012 (suppl; abstr 3586)Google Scholar
  21. Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers. Results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRefGoogle Scholar
  22. Gérard JP, Azria D, Gourgou-Bourgade S et al. (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.J ClinOncol 28:1638–1644Google Scholar
  23. Geus-Oei L, Vriens L, van Laarhoven H et al (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50:43–54CrossRefGoogle Scholar
  24. Glynne-Jones R, Anyamene N (2006) Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer? Int J Radiat Oncol Biol Phys 66(2):319–320PubMedCrossRefGoogle Scholar
  25. Glynne-Jones R, Mawdsley S, Pearce T et al (2006) Alternative clinical end points in rectal cancer—are we getting closer? Ann Oncol 17:1239–1248PubMedCrossRefGoogle Scholar
  26. Guillem J, MD Moore H, Akhurst T et al (2004) Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199:1–7PubMedCrossRefGoogle Scholar
  27. Gunderson LL, Sargent DJ, Tepper JE et al (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22:1785–1796PubMedCrossRefGoogle Scholar
  28. Habr-Gama A, Perez RO, Nadalin W et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–717PubMedGoogle Scholar
  29. Hofheinz R, Wenz R, Post S et al. (2011) Capecitabine (Cape) versus 5-fluorouracil–based (neo)adjuvant chemoradiotherapy for locally advanced rectal cancer: long-term results of a randomized, phase III trial. J Clin Oncol 29 (suppl; abstr 3504)Google Scholar
  30. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRefGoogle Scholar
  31. Liersch T, Langer C, Ghadimi M et al (2006) Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 24:4062–4068PubMedCrossRefGoogle Scholar
  32. Maas M, Nelemans P, Valentini V et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11:835–844PubMedCrossRefGoogle Scholar
  33. Maas M, Beets-Tan R, Lambregts D et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640PubMedCrossRefGoogle Scholar
  34. Madelon PJ et al (2010) A systematic methodology review of phase I radiation dose escalation trials. Radiother Oncol 95:135–141CrossRefGoogle Scholar
  35. Methy N, Bedenne L, Conroy T et al (2010) Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol 21:518–524PubMedCrossRefGoogle Scholar
  36. Nagtegaal I, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303–312PubMedCrossRefGoogle Scholar
  37. Nagtegaal ID, Marijnen CAM, Klein Kranenbarg E et al (2002) Circumferential margin is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeters is the limit. Am J Surg Pathol 26:350–357PubMedCrossRefGoogle Scholar
  38. Ngan S, Fisher R, Goldstein D et al (2010) TROG, AGITG, CSSANZ, and RACS. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS) [abstract no. 3509]. J Clin Oncol 28(15 Suppl.):3509Google Scholar
  39. Onaitis MW, Noone RB, Fields R et al (2001) Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 8:801–806PubMedCrossRefGoogle Scholar
  40. Patel U, Taylor F, Blomqvist L et al (2011) Magnetic resonance imaging–detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29:3753–3760PubMedCrossRefGoogle Scholar
  41. Peeters KCMJ, Marijnen CAM, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701PubMedCrossRefGoogle Scholar
  42. Quirke P, Durdey P, Dixon MF et al (1986) Local recurrence of rectal adenocarcinoma due to inade- quate surgical resection: Histopathological study of lateral tumor spread and surgical excision. Lancet 2:996–999PubMedCrossRefGoogle Scholar
  43. Rodel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRefGoogle Scholar
  44. Roedel C et al. (2011) Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. ASCO annual meeting abstract no: LBA3505Google Scholar
  45. Roh MS, Colangelo LH, O’Connell MJ et al (2009) Pre-operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum (NSABP-R-03). J Clin Oncol 27:5124–5130PubMedCrossRefGoogle Scholar
  46. Roh MS, Yothers GA, O’Connell MJ et al. (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29 (suppl; abstr 3503)Google Scholar
  47. Sargent D, Wieand H, Haller D et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670PubMedCrossRefGoogle Scholar
  48. Sargent D, Shi Q, Yothers G et al (2011) Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47(7):990–996PubMedCrossRefGoogle Scholar
  49. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 1731:351–402Google Scholar
  50. Sauer R, Liersch T, Merkel S et al. (2011) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. Proc ASCO 29:225 s (abstr)Google Scholar
  51. Schrag MR, Weiser KA, Goodman KA et al (2010) Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer [abstract no. 3511]. J Clin Oncol 28(15 Suppl.):3511Google Scholar
  52. Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicenter, randomised trial. Lancet 373:811–820PubMedCrossRefGoogle Scholar
  53. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol 4:86–100PubMedCrossRefGoogle Scholar
  54. Tepper J, O’Connell M, Niedzwiecki D et al (2002) Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol 20:1744–1750PubMedCrossRefGoogle Scholar
  55. Tepper J, Wang A (2010) Improving local control in rectal cancer: radiation sensitizers or radiation dose? J Clin Oncol 1:1623–1624CrossRefGoogle Scholar
  56. Valentini V, Coco C, Picciocchi A et al (2002) Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53(3):664–674PubMedCrossRefGoogle Scholar
  57. Vecchio F, Valentini V, Minsky B et al (2005) The relationship of pathologic tumor regression grade (trg) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62(3):752–760PubMedCrossRefGoogle Scholar
  58. Wheeler JM, Warren BF, Mortensen NJ et al (2002) Quantification of histologic regression of rectal cancer after irradiation. Dis Colon Rectum 45:1051–1056PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Carlos Fernandez-Martos
    • 1
  • Angel Guerrero
    • 2
  • Bruce Minsky
    • 3
  1. 1.Gastointestinal Oncology Unit, Medical Oncology DepartmentFundacion Instituto Valenciano de OncologiaValenciaSpain
  2. 2.Medical Oncology DepartmentFundacion Instituto Valenciano de OncologiaValenciaSpain
  3. 3.Department of Radiation OncologyMD Anderson Cancer CenterHoustonUSA

Personalised recommendations